Article Abstract

Is the onset of adverse effects of immunotherapy always bad news for the patients…?—certainly not!

Authors: Paul Hofman


Despite the identification of promising and validated biomarkers the response to immunotherapy can be unexpected or variable, including rapid regression (complete or partial) of the tumor mass, stability, progression, pseudo progression or hyper tumor progression (1-5). Immunotherapy, in general, is less toxic than chemotherapy for patients with cancer.